Income Statement Shanghai Shyndec Pharmaceutical Co., Ltd.
Equities
600420
CNE000001JG2
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.28 CNY | +1.82% | +0.82% | +25.43% |
Dec. 06 | Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials | MT |
Dec. 03 | Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 12.05B | 12.41B | 13.76B | 12.81B | 11.79B | |||||
Other Revenues, Total | 149M | 148M | 189M | 150M | 283M | |||||
Total Revenues | 12.2B | 12.56B | 13.94B | 12.96B | 12.07B | |||||
Cost of Goods Sold, Total | 6.17B | 6.77B | 7.91B | 8.09B | 7.54B | |||||
Gross Profit | 6.03B | 5.79B | 6.04B | 4.87B | 4.53B | |||||
Selling General & Admin Expenses, Total | 4.33B | 4.05B | 4.22B | 3.41B | 2.91B | |||||
Provision for Bad Debts | 6.76M | 26.24M | 24.87M | -17.59M | -18.05M | |||||
R&D Expenses | 417M | 494M | 585M | 517M | 562M | |||||
Other Operating Expenses | 134M | 127M | 128M | 113M | 115M | |||||
Other Operating Expenses, Total | 4.89B | 4.7B | 4.96B | 4.03B | 3.57B | |||||
Operating Income | 1.14B | 1.09B | 1.08B | 841M | 967M | |||||
Interest Expense, Total | -189M | -124M | -110M | -107M | -57.88M | |||||
Interest And Investment Income | 51.65M | 36.78M | 48.84M | 61.69M | 136M | |||||
Net Interest Expenses | -138M | -86.73M | -61.62M | -45.62M | 78.59M | |||||
Currency Exchange Gains (Loss) | 21.74M | -64.01M | -32.65M | 98.32M | 28.44M | |||||
Other Non Operating Income (Expenses) | -10.17M | -9.6M | -5.75M | -4.23M | -4.09M | |||||
EBT, Excl. Unusual Items | 1.01B | 935M | 978M | 890M | 1.07B | |||||
Impairment of Goodwill | - | -44.76M | -132M | - | - | |||||
Gain (Loss) On Sale Of Investments | -42.81M | -21.81M | -24.04M | - | - | |||||
Gain (Loss) On Sale Of Assets | -14.57M | 21.15M | 203K | -1.1M | -31.85M | |||||
Asset Writedown | -753K | -1.73M | -10.81M | -4.93M | -13.66M | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | 119M | 154M | 107M | 100M | 71.77M | |||||
EBT, Incl. Unusual Items | 1.07B | 1.04B | 918M | 984M | 1.1B | |||||
Income Tax Expense | 144M | 141M | 97.06M | 117M | 132M | |||||
Earnings From Continuing Operations | 928M | 900M | 821M | 867M | 965M | |||||
Net Income to Company | 928M | 900M | 821M | 867M | 965M | |||||
Minority Interest | -272M | -251M | -253M | -240M | -273M | |||||
Net Income - (IS) | 656M | 649M | 568M | 628M | 692M | |||||
Net Income to Common Incl Extra Items | 656M | 649M | 568M | 628M | 692M | |||||
Net Income to Common Excl. Extra Items | 656M | 649M | 568M | 628M | 692M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.62 | 0.63 | 0.55 | 0.61 | 0.54 | |||||
Basic EPS - Continuing Operations | 0.62 | 0.63 | 0.55 | 0.61 | 0.54 | |||||
Basic Weighted Average Shares Outstanding | 1.05B | 1.03B | 1.03B | 1.03B | 1.27B | |||||
Net EPS - Diluted | 0.57 | 0.55 | 0.48 | 0.54 | 0.54 | |||||
Diluted EPS - Continuing Operations | 0.57 | 0.55 | 0.48 | 0.54 | 0.54 | |||||
Diluted Weighted Average Shares Outstanding | 1.15B | 1.18B | 1.18B | 1.16B | 1.27B | |||||
Normalized Basic EPS | 0.34 | 0.32 | 0.35 | 0.31 | 0.31 | |||||
Normalized Diluted EPS | 0.31 | 0.28 | 0.3 | 0.27 | 0.31 | |||||
Dividend Per Share | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Payout Ratio | 49.44 | 32.42 | 37.39 | 29.42 | 27.37 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.86B | 1.82B | 1.85B | 1.67B | 1.77B | |||||
EBITA | 1.18B | 1.12B | 1.11B | 874M | 999M | |||||
EBIT | 1.14B | 1.09B | 1.08B | 841M | 967M | |||||
EBITDAR | 1.91B | 1.86B | 1.91B | 1.69B | 1.8B | |||||
Total Revenues (As Reported) | 12.2B | 12.56B | 13.94B | 12.96B | 12.07B | |||||
Effective Tax Rate - (Ratio) | 13.46 | 13.55 | 10.57 | 11.85 | 12.03 | |||||
Total Current Taxes | 74.7M | 123M | 125M | 174M | 143M | |||||
Total Deferred Taxes | 69.69M | 17.64M | -27.54M | -56.98M | -11.45M | |||||
Normalized Net Income | 360M | 333M | 358M | 316M | 396M | |||||
Interest Capitalized | 34.26M | 35.42M | 38.56M | 29.27M | - | |||||
Interest on Long-Term Debt | 344M | 94.43M | 67.73M | - | - | |||||
Non-Cash Pension Expense | 55.97K | -203K | 421K | -32.79K | 224K | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 7.59M | 6.43M | 7.1M | 3.29M | 4.64M | |||||
Marketing Expenses | - | 1.31M | - | - | - | |||||
Selling and Marketing Expenses | 3.6B | 3.39B | 3.48B | 2.74B | 2.15B | |||||
General and Administrative Expenses | 698M | 630M | 722M | 652M | 744M | |||||
Research And Development Expense From Footnotes | 429M | 511M | 603M | 539M | 586M | |||||
Net Rental Expense, Total | 51.22M | 45.13M | 56.59M | 28.89M | 29.52M | |||||
Imputed Operating Lease Interest Expense | 24.15M | 13.54M | 16.89M | 8.32M | 6.01M | |||||
Imputed Operating Lease Depreciation | 27.07M | 31.59M | 39.69M | 20.57M | 23.51M | |||||
Maintenance & Repair Expenses, Total | - | 89.96M | 18.5M | 19.71M | 25M |